Abterra Biosciences
Abterra Biosciences is a biotechnology company specializing in next-generation antibody therapeutics development. They leverage advanced technologies including next-generation sequencing, mass spectrometry, and machine learning to comprehensively map antibody responses and rapidly identify superior therapeutic antibodies. Their product portfolio includes platforms such as Reptor for B-cell receptor sequencing, Alicanto for custom antibody discovery from serum, Valens for monoclonal antibody protein sequencing and confirmation, and Griffin for polyclonal antibody sequencing without the need for B cells. Founded as a spin-out from the University of California San Diego, Abterra combines expertise in bioinformatics and computational mass spectrometry to deliver innovative antibody sequencing and discovery solutions. The company serves research institutions and biotech companies aiming to accelerate antibody therapeutic development with high-quality sequencing data and analysis.
Abterra Biosciences
Abterra Biosciences is a biotechnology company specializing in next-generation antibody therapeutics development. They leverage advanced technologies including next-generation sequencing, mass spectrometry, and machine learning to comprehensively map antibody responses and rapidly identify superior therapeutic antibodies. Their product portfolio includes platforms such as Reptor for B-cell receptor sequencing, Alicanto for custom antibody discovery from serum, Valens for monoclonal antibody protein sequencing and confirmation, and Griffin for polyclonal antibody sequencing without the need for B cells. Founded as a spin-out from the University of California San Diego, Abterra combines expertise in bioinformatics and computational mass spectrometry to deliver innovative antibody sequencing and discovery solutions. The company serves research institutions and biotech companies aiming to accelerate antibody therapeutic development with high-quality sequencing data and analysis.